A Phase 2 Study of a Non-myeloablative Allogeneic Stem Cell Transplant with Peri-transplant Rituximab in Patients with B-cell Lymphoid Malignancies: Favorably Durable Event-free Survival in Chemosensitive Patients

The aim of this prospective phase II trial was to determine the safety and efficacy of a nonmyeloablative (NMA) conditioning program incorporating peri-transplant-rituximab in patients with CD20+ B-cell non-Hodgkin lymphoma (B-NHL) receiving an allogeneic stem cell transplant (allo-SCT). Fifty-one a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biol Blood Marrow Transplant
Autori principali: Sauter, Craig S., Barker, Juliet N., Lechner, Lauren, Zheng, Junting, Devlin, Sean M., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Jakubowski, Ann A., Goldberg, Jenna D., Koehne, Guenther, Ceberio, Izaskun, Giralt, Sergio, Zelenetz, Andrew D., Moskowitz, Craig H., Castro-Malaspina, Hugo
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4374345/
https://ncbi.nlm.nih.gov/pubmed/24315843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.11.029
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi